Singapore's S*BIO Expands Collaboration With Onyx On JAK2 Inhibitors

PERTH, Australia - Singapore-based S*BIO and U.S.-based Onyx Pharmaceuticals are expanding their development collaboration to include additional indications for S*BIO's novel JAK2 inhibitors, the companies announced May 4